Clinical studies have also confirmed that CD4 + CD25 + Tregs are recruited to tumor sites by recombinant human C-C motif chemokine 22 protein (CCL22) secreted by ovarian cancer cells, resulting in the accumulation of CD4 + CD25 + Tregs in cancer tissues. This evidence concerns the gene CCL22 and cancer.